V
VentureMed Group
Endovascular products to treat patients suffering from peripheral artery disease (PAD)
About VentureMed Group
VentureMed Group, Inc. develops and markets innovative endovascular medical devices designed to address unmet medical needs in the treatment of Peripheral Artery Disease (PAD) and stenoses of arteriovenous (AV) fistulas and grafts. The company's core product, the FLEX Vessel Prep™ System, is engineered to optimize PAD revascularization by creating controlled, long, micro incisions in complex lesions. This system enhances the effectiveness of Percutaneous Transluminal Angioplasty (PTA) and other final therapies by modifying plaque in mixed morphology and asymmetrical lesions, thereby improving drug access to diseased vessels.
Read full description
VentureMed operates in the medical device market, primarily serving healthcare providers and patients suffering from PAD and related vascular conditions. The business model revolves around the development, marketing, and sales of its proprietary medical devices. Revenue is generated through the direct sale of these devices to hospitals, clinics, and other healthcare facilities.
The company focuses on providing solutions that ensure consistent and safe vessel preparation, aiming to improve patient outcomes and facilitate more effective treatments. By addressing the complexities of vascular conditions with precise and controlled interventions, VentureMed positions itself as a key player in the endovascular treatment landscape.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Toledo, United States
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 89.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Patient Care, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning VentureMed Group.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2025 | $28M | $112M | Endeavour Vision · S3 Ventures | ↗ |
| DEBTDebt | Dec 2023 | $2M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for VentureMed Group is 4.4K monthly website visits, up 1529.6% over the last three months. VentureMed Group's team grew 50% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- RVRocket Ventures
Series A2 investors entered at this stage
Endeavour Vision
RiverVest Venture Partners
Series B and later1 investor entered at this stage
S3 Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VentureMed Group on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VentureMed Group’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.